The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

Integrating people-centered HIV care with primary health care is essential to improving access, equity and health outcomes, but doing so successfully requires coordinated policies, digital ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The U.S. Senate has opened debate on a $9 billion rescission bill to claw back foreign aid and other funding not aligned with ...

PEPFAR has been one of the greatest success stories in global health, transforming the HIV response,” IAS President Beatriz Grinsztejn said. “Global advocacy played a crucial role in persuading US ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The World Health Organization (WHO) chief on Monday called on world leaders to prioritize HIV prevention and embrace ...